RELATING TO STATE AFFAIRS AND GOVERNMENT -- THE RHODE ISLAND, MEDICAID REFORM ACT OF 2008
S2666 amends Rhode Island’s Medicaid Reform Act of 2008 to require Medicaid coverage for a new category of fertility-related benefits beginning January 1, 2027. The bill defines key terms such as infertility, fertility diagnostic care, intrauterine insemination, and standard fertility preservation services, and it specifies that covered preservation services include counseling, testing, medications, procedures, cryopreservation, and storage of reproductive material. Coverage for storage would extend until age 30 or five years, whichever is later, with the option for a longer period.
The bill also requires Medicaid coverage for infertility treatment, including medically necessary ovulation-enhancing medications and related monitoring for at least three cycles, and at least six cycles of intrauterine insemination. If ovulation-enhancing medication produces a response that makes IUI inappropriate, the bill requires coverage for in vitro fertilization and embryo transfer if recommended by the treating physician. The bill prohibits waiting periods, exclusions based on prior diagnosis, disability, prior fertility treatment, or use of donor gametes, and bars differential treatment based on protected characteristics such as age, ancestry, disability, gender identity, genetic information, marital status, race, religion, sex, or sexual orientation.
If enacted, the bill would expand Rhode Island Medicaid benefits and impose new coverage obligations on the executive office of health and human services for both fee-for-service and managed care Medicaid plans. It would effectively add fertility diagnosis, fertility preservation, ovulation-inducing medication, intrauterine insemination, and potentially IVF/embryo transfer to the state Medicaid benefit package, subject to the bill’s conditions and timing. The bill also directs EOHHS to report to legislative leaders by January 1, 2027, after consulting with CMS, on whether IVF is medically reasonable and necessary under federal law, how it could be covered under Medicaid, and what state and federal funding would be needed.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of expanding reproductive health coverage, with the proposal framed as a Medicaid access and equity measure. The bill’s detailed nondiscrimination language and explicit coverage mandates suggest an intent to broaden access for people facing infertility or fertility-threatening medical conditions. No opposing arguments, amendments, or recorded roll-call votes are included in the provided context.
The main potential point of contention is cost and federal compliance. The bill requires a legislative report on whether IVF can be covered as a Medicaid benefit under federal law and what funding would be required, indicating uncertainty about federal authority, waiver options, and fiscal impact. Another likely area of debate is the scope of mandated fertility coverage, including the minimum number of medication cycles and IUI cycles, the storage requirement for preserved reproductive material, and the inclusion of IVF when IUI is contraindicated. The bill’s nondiscrimination provisions and coverage for people using donor gametes may also be debated by those concerned about program scope or policy limits.